--- title: "AbCellera Biologics (ABCL) news: offering" url: "https://aibio.space/companies/abcellera-biologics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ABCL offering news: AbCellera launches $200,000,000 share offering, then prices it at $9.75. AbCellera Biologics Inc. (NASDAQ: ABCL), Canada." --- ABCL AbCellera Biologics Inc. NASDAQ · Canada # AbCellera Biologics (ABCL) news ABCL offering news Financings · 2026-08-11 ## [AbCellera launches $200,000,000 share offering, then prices it at $9.75](https://aibio.space/news/abcellera-launches-200-000-000-share-offering-then-prices-9-75/) A later announcement prices 17,435,897 common shares and pre-funded warrants for 3,076,926 shares, for expected gross proceeds of about $200.0 million. The offering is expected to close on August 14, 2026. ## Latest AbCellera Biologics news 1. 2025-02-27 Financings [AbCellera Biologics files automatic shelf registration for shares, debt and warrants](https://aibio.space/news/abcellera-biologics-files-automatic-shelf-registration-shares-debt/) AbCellera's common shares last sold at $2.92 per share on February 26, 2025. The prospectus sets no dollar amount for the offerings and names no bank or agent. ## AbCellera Biologics at a glance - **Ticker**: ABCL - **Listing**: NASDAQ - **Country**: Canada - **Cash, Jun 30, 2026**: $120.1 million ### Related companies - [Hemostemix](https://aibio.space/companies/hemostemix/) TSXV: HEM - [BriaCell Therapeutics](https://aibio.space/companies/briacell-therapeutics/) TSX: BCT - [Quantum Biopharma](https://aibio.space/companies/quantum-biopharma/) NASDAQ: QNTM - [Rapid Dose Therapeutics](https://aibio.space/companies/rapid-dose-therapeutics/) CSE: DOSE - [Cardiol Therapeutics](https://aibio.space/companies/cardiol-therapeutics/) TSX: CRDL - [ZENITH CAPITAL CORPORATION](https://aibio.space/companies/zenith-capital/) OTC: ZHCLF - [IMV INC](https://aibio.space/companies/imv/) OTC: IMVIF - [Medicus Pharma](https://aibio.space/companies/medicus-pharma/) NASDAQ: MDCX ### Also on NASDAQ - [Palatin Technologies](https://aibio.space/companies/palatin-technologies/) PTN - [Oruka Therapeutics](https://aibio.space/companies/oruka-therapeutics/) ORKA - [Neumora Therapeutics](https://aibio.space/companies/neumora-therapeutics/) NMRA - [MetaVia](https://aibio.space/companies/metavia/) MTVA - [MiNK Therapeutics](https://aibio.space/companies/mink-therapeutics/) INKT - [Nautilus Biotechnology](https://aibio.space/companies/nautilus-biotechnology/) NAUT ## What AbCellera Biologics does AbCellera is a clinical-stage biotechnology company that discovers and develops first-in-class antibody medicines for indications with high unmet medical need. It has moved from using its platform mainly for partners' programs to building its own pipeline. Its lead candidate, ABCL635, is a potential non-hormonal medicine for moderate-to-severe vasomotor symptoms, also known as hot flashes, associated with menopause, and it targets the Neurokinin-3 Receptor. ABCL575, a potential best-in-class antibody targeting OX40 Ligand, is in a Phase 1 trial in Canada for atopic dermatitis and other immunology and inflammation conditions. Two further development candidates, ABCL688 for autoimmune conditions and ABCL386 for oncology, are in IND-enabling activities, and the company anticipates Phase 1/2 trials for both in 2027. The company says its platform targets complex transmembrane proteins, multispecific antibodies and antibody-drug conjugates. It opened a clinical manufacturing facility in Vancouver, which the text describes as 130,000 square feet. | Product or program | What it is | Stage | |---|---|---| | ABCL635 | Antibody for non-hormonal treatment of menopause-associated hot flashes | Phase 1/2 | | ABCL575 | Antibody for atopic dermatitis and other I&I conditions | Phase 1 | | ABCL688 | Antibody for autoimmune conditions | IND-enabling studies | | ABCL386 | Antibody for oncology | IND-enabling activities | Summarised from the company's [10-K filed Feb 24, 2026](https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm). ## AbCellera Biologics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$75.1 million](https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/) | [$28.8 million](https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/) | | Research and development | [$186.8 million](https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/) | [$167.3 million](https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/) | | Net income (loss) | [-$146.4 million](https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/) | [-$162.9 million](https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/) | | Cash from operations | [-$131.3 million](https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/) | [-$108.6 million](https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/) | | Cash and equivalents | [$128.5 million](https://www.sec.gov/Archives/edgar/data/1703057/000170305726000046/) | [$156.3 million](https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $120.1 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about AbCellera Biologics Has AbCellera Biologics raised money recently? Our latest story on this, dated Aug 11, 2026: "AbCellera launches $200,000,000 share offering, then prices it at $9.75". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/abcellera-launches-200-000-000-share-offering-then-prices-9-75/). What is the ticker symbol of AbCellera Biologics? AbCellera Biologics Inc. trades under the ticker ABCL on NASDAQ. Where is AbCellera Biologics listed? AbCellera Biologics Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:8QQ; LS:A2QKXS; LSX:A2QKXS. What is the SEC CIK of AbCellera Biologics? The SEC Central Index Key (CIK) for AbCellera Biologics Inc. is 1703057. Its filings are on SEC EDGAR. How many shares does AbCellera Biologics have outstanding? 306,611,466 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-05. Which country or territory is AbCellera Biologics listed under? Our directory records AbCellera Biologics Inc. under Canada. What does AbCellera Biologics do? Our directory classifies AbCellera Biologics Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of AbCellera Biologics? The ISIN recorded for AbCellera Biologics Inc. is CA00288U1066. Does aibio.space cover AbCellera Biologics? aibio.space lists AbCellera Biologics Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is AbCellera Biologics incorporated? SEC records list its state or country of incorporation as A1. What does AbCellera Biologics develop? AbCellera is a clinical-stage biotechnology company that discovers and develops first-in-class antibody medicines for indications with high unmet medical need. It has moved from using its platform mainly for partners' programs to building its own pipeline. What is ABCL635 from AbCellera Biologics? ABCL635: Antibody for non-hormonal treatment of menopause-associated hot flashes Stage: Phase 1/2. What is ABCL575 from AbCellera Biologics? ABCL575: Antibody for atopic dermatitis and other I&I conditions Stage: Phase 1. What was AbCellera Biologics's revenue last year? $75.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is AbCellera Biologics profitable? AbCellera Biologics Inc. reported a net loss of $146.4 million for the fiscal year ended Dec 31, 2025, and used $131.3 million of cash in operations, per its annual report to the SEC. ## Investor discussion: AbCellera Biologics Members talk about AbCellera Biologics (ABCL). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at AbCellera Biologics, newest first. Each line links the filing it comes from. 1. 2026-08-11 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1703057/000119312526344944/d112521d424b5.htm) 2. 2025-11-28 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1703057/000170305725000032/abcl-20251124.htm) 3. 2025-02-27 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1703057/000119312525039391/d918547ds3asr.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ABCL on TradingView](https://www.tradingview.com/symbols/NASDAQ-ABCL/). ## SEC filings and registration - **SEC name**: AbCellera Biologics Inc. - **CIK**: 1703057 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ABCL (Nasdaq) - **State or country of incorporation**: A1 - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 150 W 4TH AVENUE, VANCOUVER, British Columbia, Canada, V5Y 1G6 - **Phone**: (604) 559-9005 - **Shares outstanding**: 306,611,466 as of 2026-08-03 (10-Q filed 2026-08-05) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1703057/000119312526349353/d20959d8k.htm) filed 2026-08-13 - [424B5](https://www.sec.gov/Archives/edgar/data/1703057/000119312526349333/d112521d424b5.htm) filed 2026-08-13 - [424B5](https://www.sec.gov/Archives/edgar/data/1703057/000119312526344944/d112521d424b5.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1703057/000170305726000053/abcl-20260810.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1703057/000170305726000049/abcl-20260807.htm) filed 2026-08-07 - [10-Q](https://www.sec.gov/Archives/edgar/data/1703057/000170305726000046/abcl-20260630.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1703057/000170305726000044/abcl-20260805.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1703057/000170305726000039/abcl-20260729.htm) filed 2026-07-29 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001703057), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details AbCellera Biologics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ABCL, recorded under Canada. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: AbCellera Biologics Inc. - **Ticker**: ABCL - **Listing**: NASDAQ - **Country or territory**: Canada - **Business scope**: Biotechnology - **ISIN**: CA00288U1066 - **Other listed symbols**: GETTEX:8QQ; LS:A2QKXS; LSX:A2QKXS - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ABCL/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/abcellera-biologics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "AbCellera Biologics (ABCL) news: offering", 2026-10-31, https://aibio.space/companies/abcellera-biologics/